Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Manasa Kanthamneni"'
Autor:
Lauren N. Koenig, Gregory S. Day, Amber Salter, Sarah Keefe, Laura M. Marple, Justin Long, Pamela LaMontagne, Parinaz Massoumazada, B. Joy Snider, Manasa Kanthamneni, Cyrus A. Raji, Nupur Ghoshal, Brian A. Gordon, Michelle Miller-Thomas, John C. Morris, Joshua S. Shimony, Tammie L.S. Benzinger
Publikováno v:
NeuroImage: Clinical, Vol 26, Iss , Pp - (2020)
Introduction: Volumetric biomarkers for Alzheimer disease (AD) are attractive due to their wide availability and ease of administration, but have traditionally shown lower diagnostic accuracy than measures of neuropathological contributors to AD. Our
Externí odkaz:
https://doaj.org/article/7eb1e21ee44f424e90fd20f0cc37cf41
Autor:
Biao Xiang, Matthew R Brier, Manasa Kanthamneni, Jie Wen, Abraham Z Snyder, Dmitriy A Yablonskiy, Anne H Cross
Publikováno v:
Mult Scler
Background: Imaging biomarkers of progressive multiple sclerosis (MS) are needed. Quantitative gradient recalled echo (qGRE) magnetic resonance imaging (MRI) evaluates microstructural tissue damage in MS. Objective: To evaluate qGRE-derived R2t* as a
Autor:
Manasa Kanthamneni, Jie Wen, Anne H. Cross, Dmitriy A. Yablonskiy, Biao Xiang, Abraham Z. Snyder, Matthew R. Brier
BackgroundImaging biomarkers of progressive MS are needed. Quantitative gradient recalled echo (qGRE) MRI technique allows evaluation of tissue damage associated with microstructural damage in multiple sclerosis (MS).ObjectiveTo evaluate qGRE-derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6c761206a86e681edb2d33e5f1ed6ce
https://doi.org/10.1101/2021.08.18.21262247
https://doi.org/10.1101/2021.08.18.21262247
Publikováno v:
Blood. 112:3290-3290
Background: Alemtuzumab (Campath-1H), a depleting humanized monoclonal antibody against CD52 has been successfully used for immunosuppression in reduced intensity transplantation (RIT) for non-malignant disorders in children (Shenoy et al, BMT 2005).